CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Published online: 20 November 2017; doi:10.1038/nm.4441

Fry et al. report the first results from a human trial of a CD22-directed chimeric antigen receptor (CAR) T cell therapy providing evidence of efficacy in the treatment of pre–B cell acute lymphoblastic leukemia that is immunotherapy-naive or resistant to CD19-directed CAR T cells.

中文翻译：

---

靶向CD22的CAR T细胞诱导B-ALL的缓解

靶向CD22的CAR T细胞诱导B-ALL的缓解

靶向CD22的CAR T细胞可诱导B-ALL的缓解，该反应对CD19靶向CAR免疫治疗是天真的或具有抗性，在线发布：2017年11月20日; doi：10.1038 / nm.4441

Fry等。报告了一项针对CD22定向嵌合抗原受体（CAR）T细胞疗法的人类试验的首项研究结果，为治疗未经免疫治疗或对CD19定向CAR T耐药的前B细胞急性淋巴细胞白血病提供了有效的证据。细胞。